By contrast, knockdown of NRF2 in Casik cervical cancer cells, A549 non-small-cell lung cancer cells, and prostate cancer cells increased sensitivity to chemotherapeutic drugs and radiation [25,31–32]. Here, NFE2L2 is linked to prostate carcinoma.